← All trials
NCT03605719
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2019
- Primary completion
- Jul 31, 2022
- Completion date
- Jul 31, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 62
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Emory UniversityLead sponsor
- City of Hope National Medical CenterCollaborator
- Emory UniversityOverall official - principal investigator
- Emory UniversityReponsible party - principal investigator
- National Cancer Institute (NCI)Collaborator
- National Institutes of Health (NIH)Collaborator
- Oncolytics BiotechCollaborator
- PhylogenyCollaborator
- University of UtahCollaborator
- Emory UniversitySponsor investigator
- Bristol-Myers SquibbCollaborator
- Emory UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.